{"favorite_id": 3826, "calc_type": "calculator", "dosing": false, "full_title_en": "ACC/AHA Heart Failure Staging", "short_title_en": "ACC/AHA Heart Failure Staging", "medium_description_en": "Describes stages of heart failure and provides recommendations for therapy by stage.", "short_description_en": "Heart failure staging and therapy recommendations.", "before_use": "", "instructions_en": "", "purpose_en": ["Prognosis"], "disease_en": ["Heart Failure"], "specialty_en": ["Cardiology"], "chief_complaint_en": ["Chest Pain", "Extremity Edema", "Shortness of Breath"], "system_en": ["Cardiac"], "search_abbreviation_en": ["ACC/AHA Heart Failure Staging tool", "heart failure staging tool", "heart failure stages", "hf stages"], "slug": "acc-aha-heart-failure-staging", "seo": {"meta_description_en": "The ACC/AHA Heart Failure Staging tool describes stages of heart failure and provides recommendations for therapy by stage.", "keywords_en": "heart failure stages, hf stages, heart failure treatment, hf treatment, hf tx, treatment guidelines heart failure"}, "content": {"how_to_use": {"use_case_en": "<ul> <li>Patients with known heart failure.</li> <li>Patients at risk for heart failure.</li> </ul>", "pearls_pitfalls_en": "<ul> <li>Developed jointly by the American College of Cardiology (ACC) and American Heart Association (AHA) to complement, but not replace, the more widely-used New York Heart Association (NYHA) functional classification.</li> <li>Based on expert consensus.</li> </ul>", "why_use_en": "<ul> <li>Matches stage to treatment options, unlike other classification systems.</li> <li>Other heart failure classification systems include Forrester Class and NYHA Class.</li> <li>Unlike other classification systems, the ACC/AHA stages include patients at risk for heart failure and corresponding management options.</li> </ul>"}, "next_steps": {"advice_en": "<p>Consider treatment based on stage.</p>", "management_en": "", "critical_actions_en": ""}, "about": {"formula_en": "<ul> <li><strong>Stage A:</strong> High risk for developing HF but no structural disorder of the heart</li> <li><strong>Stage B:</strong> Structural disorder of the heart but has never developed symptoms of HF</li> <li><strong>Stage C:</strong> Past or current symptoms of HF associated with underlying structural heart disease</li> <li><strong>Stage D:</strong> End-stage disease requiring specialized treatment strategies such as mechanical circulatory support, continuous inotropic infusions, cardiac transplantation, or hospice care</li> </ul>", "more_info_en": "<table> <tbody> <tr> <td>Stage</td> <td>Class I recommendations*</td> </tr> <tr> <td>A</td> <td> <ol> <li>Control of systolic and diastolic hypertension in accordance with recommended guidelines. (Level of Evidence: A)</li> <li>Treatment of lipid disorders in accordance with recommended guidelines. (Level of Evidence: B)</li> <li>Avoidance of patient behaviors that may increase the risk of HF (e.g., smoking, alcohol consumption, and illicit drug use). (Level of Evidence: C)</li> <li>Angiotensin converting enzyme (ACE) inhibition in patients with a history of atherosclerotic vascular disease, diabetes mellitus, or hypertension and associated cardiovascular risk factors. (Level of Evidence: B)</li> <li>Control of ventricular rate in patients with supraventricular tachyarrhythmias. (Level of Evidence: B)</li> <li>Treatment of thyroid disorders. (Level of Evidence: C)</li> <li>Periodic evaluation for signs and symptoms of HF. (Level of Evidence: C)</li> </ol> </td> </tr> <tr> <td>B</td> <td> <ol> <li>ACE inhibition in patients with a recent or remote history of myocardial infarction regardless of ejection fraction. (Level of Evidence: A)</li> <li>ACE inhibition in patients with a reduced ejection fraction, whether or not they have experienced a myocardial infarction. (Level of Evidence: B)</li> <li>Beta-blockade in patients with a recent myocardial infarction regardless of ejection fraction. (Level of Evidence: A)</li> <li>Beta-blockade in patients with a reduced ejection fraction, whether or not they have experienced a myocardial infarction. (Level of Evidence: B)</li> <li>Valve replacement or repair for patients with hemodynamically significant valvular stenosis or regurgitation. (Level of Evidence: B)</li> <li>Regular evaluation for signs and symptoms of HF. (Level of Evidence: C)</li> <li>Measures listed as class I recommendations for patients in stage A. (Levels of Evidence: A, B, and C as appropriate).</li> </ol> </td> </tr> <tr> <td>C</td> <td> <ol> <li>Diuretics in patients who have evidence of fluid retention. (Level of Evidence: A)</li> <li>ACE inhibition in all patients unless contraindicated. (Level of Evidence: A)</li> <li>Beta-adrenergic blockade in all stable patients unless contraindicated. Patients should have no or minimal evidence of fluid retention and should not have required treatment recently with an intravenous positive inotropic agent. (Level of Evidence: A)</li> <li>Digitalis for the treatment of symptoms of HF, unless contraindicated. (Level of Evidence: A)</li> <li>Withdrawal of drugs known to adversely affect the clinical status of patients (e.g., nonsteroidal anti-inflammatory drugs, most antiarrhythmic drugs, and most calcium channel blocking drugs). (Level of Evidence: B)</li> <li>Measures listed as class I recommendations for patients in stages A and B (Levels of Evidence: A, B, and C as appropriate).</li> </ol> </td> </tr> <tr> <td>D</td> <td> <ol> <li>Meticulous identification and control of fluid retention. (Level of Evidence: B)</li> <li>Referral for cardiac transplantation in eligible patients. (Level of Evidence: B)</li> <li>Referral to an HF program with expertise in the management of refractory HF. (Level of Evidence: A)</li> <li>Measures listed as class I recommendations for patients in stages A, B, and C. (Levels of Evidence: A, B, and C as appropriate).</li> </ol> </td> </tr> </tbody> </table> <p>From <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/11738322\" target=\"_blank\">Hunt et al, 2001</a>.</p> <p>*Conditions for which there is evidence and/or general agreement that a given procedure/therapy is useful and effective. For full recommendations, see <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/11738322\" target=\"_blank\">Hunt et al, 2001</a>.</p>", "evidence_based_medicine_en": "<p>The ACC/AHA Heart Failure Stages were developed jointly by the American College of Cardiology (ACC) and American Heart Association (AHA) by expert consensus. They were intended to complement, but not replace, the more widely-used New York Heart Association (NYHA) functional classification, since contemporary treatment recommendations did not vary by class.</p>", "references_list": {"Original/Primary Reference": [{"href": "http://circ.ahajournals.org/content/104/24/2996", "text": "Hunt SA, Baker DW et al. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America. Circulation. 2001 Dec 11;104(24):2996-3007."}], "Other References": [{"href": "", "text": ""}], "Validation": [{"href": "", "text": ""}], "Clinical Practice Guidelines": [{"href": "", "text": ""}], "Manufacturer Website": [{"href": "", "text": ""}], "Outcomes": [{"href": "", "text": ""}]}}, "contributor": {"expert_name": []}, "creator": [{"name": "Dr. Sharon Hunt", "creator_info": {"about_en": "<p>Sharon Hunt, MD, is a professor of medicine at Stanford University as well as the Med Center Line. She is a member of the Cardiovascular Institute. Dr. Hunt's research focuses on cardiovascular diseases including heart failure and myocardial infarction and is a co-author on many ACC/AHA guidelines.</p>", "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-sharon-hunt.jpeg", "pubmedLink": "https://www.ncbi.nlm.nih.gov/pubmed/?term=Hunt+SA%5BAuthor%5D"}}], "related_resources": {"mdcalc_rating": {"evidence": "", "clinical": "", "popularity": ""}, "guidelines": [], "teaching": [], "videos": [], "interests": [], "partner_contact": [], "sdm_tool": []}}, "input_schema": [{"type": "toggle", "label_en": "Patient with history of hypertension, coronary artery disease, OR diabetes", "name": "ahx", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "", "show_points": false, "optional": false}, {"type": "toggle", "label_en": "Patient using cardiotoxins", "name": "ctox", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "", "show_points": false, "optional": false}, {"type": "toggle", "label_en": "Patient with family history of cardiomyopathy", "name": "cm", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "", "show_points": false, "optional": false}, {"type": "toggle", "label_en": "Patient with previous MI, LV systolic dysfunction, or asymptomatic valvular disease", "name": "bhx", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "ahx == 1", "show_points": false, "optional": false}, {"type": "toggle", "label_en": "Patient with known structural heart disease, shortness of breath and fatigue", "name": "chx", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "bhx == 1", "show_points": false, "tips_en": "Reduced exercise tolerance.", "optional": false}, {"type": "toggle", "label_en": "Patient with marked heart failure symptoms at rest, despite maximum therapy", "name": "dhx", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "chx == 1", "show_points": false, "tips_en": "Those who are recurrently hospitalized or cannot be safely discharged from the hospital without specialized interventions.", "optional": false}], "md5": "3e82c64d1ad03c78a6ba04c103c5d4fd", "related_calcs": [{"calcId": 3803, "short_title_en": "MAGGIC Risk Calculator for HF", "slug": "maggic-risk-calculator-heart-failure"}, {"calcId": 3987, "short_title_en": "NYHA Heart Failure Classification", "slug": "new-york-heart-association-nyha-functional-classification-heart-failure"}, {"calcId": 3829, "short_title_en": "GWTG-HF Risk Score", "slug": "gwtg-heart-failure-risk-score"}]}